<DOC>
	<DOCNO>NCT01534403</DOCNO>
	<brief_summary>The study open-labeled extension study continue assess safety tolerability Epratuzumab moderate severe SLE subject previously participate SL0026 [ NCT01449071 ] phase I/II trial .</brief_summary>
	<brief_title>Open Label Extension Study Epratuzumab Japanese Systemic Lupus Erythematosus ( SLE ) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Subject complete doubleblind study SL0026 [ NCT01449071 ] terminate prematurely Week 8 later SL0026 [ NCT01449071 ] due lack efficacy Women childbearing potential must agree use acceptable method birth control/Written Informed Consent Subjects active , severe SLE disease activity involve renal system active , severe , neuropsychiatric SLE , define neuropsychiatric element score British Isles Lupus Assessment Group Index ( BILAG ) level A Subjects concurrent relevant medical condition like define chronic infection high risk new significant infection Substance abuse dependence Significant hematologic abnormality History malignant cancer Subjects condition , investigator 's judgment , would make subject unsuitable inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>B-cell immunotherapy</keyword>
	<keyword>Epratuzumab</keyword>
</DOC>